domingo, 18 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 9, 2026

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

View original at finance.yahoo.com
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Eve…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The appointments further strengthen Everest's global R&D capabilities in mRNA therapeutics, and the Company will continue to invest in world-class talent to accelerate development of its mRNA programs.

    60% confidence

  • Dr. Srinivasan and Dr. Coder's deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as Everest advances its proprietary mRNA platform and broader pipeline; the appointments reflect Everest's commitment to investing in world-class talent and advancing its global mRNA strategy.

    60% confidence

  • Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing immuno-oncology therapeutics from discovery through clinical development, with expertise spanning cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,396 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development — Source | Via News | pt.VIA.NEWS